Cargando…
Antiangiogenesis Combined with Immunotherapy to Treat Advanced Small-Cell Carcinoma of the Esophagus Resistant to Chemotherapy: According to the Guidance of Next-Generation Sequencing
A 64-year-old woman admitted to our hospital with the chief complaint of swallowing obstruction was diagnosed as relapsed small-cell carcinoma of the esophagus. Complete remission (CR) was observed after six cycles of irinotecan plus cisplatin therapy. According to the results of a next-generation s...
Autores principales: | Jiang, Man, Zhang, Xiaochun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936705/ https://www.ncbi.nlm.nih.gov/pubmed/33688208 http://dx.doi.org/10.2147/OTT.S293733 |
Ejemplares similares
-
Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017) -
Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy
por: Wan, Xueting, et al.
Publicado: (2021) -
Cavity development: a potential biomarker for antiangiogenesis agents
por: Jiang, Man, et al.
Publicado: (2020) -
Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
por: Li, Song, et al.
Publicado: (2023) -
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis
por: Wang, Ji, et al.
Publicado: (2016)